Evidence map›Paper›PMID 35520058›Full record

ArticleRSC advances2020

Ultrasensitive melanoma biomarker detection using a microchip SERS immunoassay with anisotropic Au-Ag alloy nanoboxes.

Aswin Raj Kumar, Karthik Balaji Shanmugasundaram, Junrong Li, Zhen Zhang, Abu Ali Ibn Sina, Alain Wuethrich, Matt Trau

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. [FJX1 overexpression is associated with poor prognosis and promotes gastric cancer proliferationNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  2. Review
  3. Traditional vs. Microfluidic Synthesis of ZnO Nanoparticles.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

Aswin Raj KumarCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.ORCID https://orcid.org/0000-0002-5162-2163
Karthik Balaji ShanmugasundaramCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.ORCID https://orcid.org/0000-0002-0584-2122
Junrong LiCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.
Zhen ZhangCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.
Abu Ali Ibn SinaCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.ORCID https://orcid.org/0000-0001-8099-3863
Alain WuethrichCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.ORCID https://orcid.org/0000-0001-9569-0478
Matt TrauCentre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia a.wuethrich@uq.edu.au a.sina@uq.edu.au m.trau@uq.edu.au.ORCID https://orcid.org/0000-0002-2652-1985
The University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The detection of circulating biomarkers in liquid biopsies has the potential to provide a non-invasive route for earlier cancer diagnosis and treatment management. Melanoma chondroitin sulfate proteoglycan (MCSP) is a membrane protein characteristic for melanoma cell migration and tissue invasion with its soluble form (sMCSP) serving as a potential promising diagnostic surrogate. However, at the initial disease stage, the detection of sMCSP is challenging because of its low abundance and the required high specificity to analyze sMCSP in complex bodily fluids. Herein, we report a highly sensitive and high-throughput microchip that enables Surface Enhanced Raman Spectroscopy (SERS) immunoassay for parallel detection of up to 28 samples. Key to assay speed and sensitivity is the stimulation of an alternating current-induced nanofluidic mixing that improves target-sensor collision and displacement of non-specific molecules. Anisotropic Au-Ag alloy nanoboxes (NB's) with strong plasmonic hot spots provide single SERS particle sensitivity that enables ultrasensitive sMCSP detection of as low as 0.79 pM (200 pg ml

Identifiers

PMID35520058
PMCPMC9055796
OpenAlexW3047344365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.